Hepatic Encephalopathy Clinical Trial
Verified date | June 2024 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender matched and similar age control group with normal hepatic function.
Status | Completed |
Enrollment | 32 |
Est. completion date | June 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Subjects were required to fulfill the following criteria in order to participate in the study: Screening: - Males or females aged = 18 years of age - Able to provide written informed consent before any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study - Classification to one of the following: - current diagnosis of hepatic impairment with cirrhosis - healthy subject - Subjects with hepatic impairment with cirrhosis were classifiable to one of the following groups: - Child-Pugh score A - Child-Pugh score B - Child-Pugh score C - Subjects with hepatic impairment with cirrhosis who were on a therapeutic regimen of lactulose must have been on a stable dose for = 30 days prior to screening - If female, a negative pregnancy test at screening and pre-dose on day 0, or a documented sterilization procedure; a female of child-bearing potential must have been using a medically approved birth control method and must have agreed to use the same method of contraception during the full course of the study (on pre-dose day 0 as well as at screening) - Weight within the range of 60-100 kg (at screening and pre-dose on day 0) - Willing to stop taking any medication that the Sponsor and the Investigator felt was not appropriate for use during the study, beginning 2 days before dosing and throughout the study Exclusion Criteria: Subjects who fulfilled any of the following criteria were excluded from the study: Screening: - Clinically significant history or evidence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), as determined by the Investigator - Serum sodium < 120 mEq/L - Serum creatinine = 1.5 upper limit of normal - Potassium = 3.5 mEq/L - Other laboratory values outside the normal range which were determined to be clinically significant by the Investigator - Significant illness within the last 14 days - Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection - Inflammatory bowel disease or malabsorption defined with steatorrhea - Active gastrointestinal bleeding, defined as melena, hematochezia, or hematemesis requiring hospitalization within the last 30 days - Use of probenecid, valproate, or corticosteroids within the last 24 hours - Use of any medication, other than those approved by the Sponsor and Investigator, in the last 48 hours - History of seizures within the last 72 hours - Positive drugs of abuse urine test - Positive alcohol breath test - Donation or loss of blood (500 mL or more) within the last 30 days - Donation or loss of plasma within the last 7 days - History of acquired immunodeficiency syndrome (AIDS) or determined human immunodeficiency virus (HIV) positive - Hepatitis B or C (HBV; HCV) positive (healthy volunteers only) - Use of any investigational drug within the last 30 days - Known hypersensitivity to sodium phenylbutyrate or similar drugs - Emergency hospitalization within the last 90 days - Intake of alcohol in the last 7 days Pre-dose (days 0 and 7): - Significant illness or emergency hospitalization since the last study visit - Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection - Use of probenecid, valproate, or corticosteroids within the last 24 hours - Use of any non-approved medication (by the Sponsor/Investigator) within the 48 hours before dosing - History of seizures within the last 72 hours - Positive drugs of abuse urine test - Positive alcohol breath test - Donation or loss of blood (500 mL or more) or plasma since the last study visit - Use of any investigational drug since the last study visit - Intake of alcohol in the last 7 days |
Country | Name | City | State |
---|---|---|---|
Ukraine | Department of General Surgery #2; Kharkiv State Medical University | Kharkiv | |
Ukraine | National University of Pharmacy | Kharkiv |
Lead Sponsor | Collaborator |
---|---|
Amgen | Ucyclyd Pharma, Inc. |
Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of adverse event |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01559519 -
Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
|
Phase 4 | |
Terminated |
NCT01846806 -
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
|
N/A | |
Recruiting |
NCT01178372 -
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
|
Phase 4 | |
Completed |
NCT00740142 -
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
|
Phase 4 | |
Completed |
NCT00914056 -
A Study of Controlled Lactulose Withdrawal
|
N/A | |
Completed |
NCT00558038 -
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Recruiting |
NCT05539027 -
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
|
Phase 4 | |
Recruiting |
NCT04096014 -
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
|
N/A | |
Completed |
NCT05526404 -
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Enrolling by invitation |
NCT06367127 -
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
|
||
Active, not recruiting |
NCT05425316 -
Speech in Hepatic Encephalopathy (HE)
|
||
Recruiting |
NCT04415294 -
Flicker App for Minimal Hepatic Encephalopathy
|
||
Not yet recruiting |
NCT06072521 -
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT02636647 -
Fecal Transplant in Recurrent Hepatic Encephalopathy
|
Phase 1 | |
Withdrawn |
NCT02086825 -
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
|
Phase 3 | |
Completed |
NCT01446523 -
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
|
N/A | |
Completed |
NCT01218568 -
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
|
N/A | |
Completed |
NCT01008293 -
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
|
Phase 2/Phase 3 |